A Double Blind, Randomized, Placebo Controlled, Parallel Group Study of Sativex® in Relieving Persistent Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.

Status
Active
Cancer Type
Unknown Primary
Trial Phase
Phase III
Eligibility
18 and over, Male and Female
Study Type
Supportive care
NCD ID
NCT01262651
Protocol IDs
GWCA0958 (primary)
2009-016064-36
Study Sponsor
GW Pharmaceuticals

Summary

This nine week study will aim to determine the efficacy, safety and tolerability of Sativex® as an adjunctive treatment, compared with placebo in relieving uncontrolled persistent chronic pain in patients with advance cancer.

Eligible patients will not be required to stop any of their current treatments or medications.